Literature DB >> 16982097

Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.

Yong Xu1, Jessica McDonald, Emily Perloff, Giovanna Butticè, Barbara M Schreiber, Barbara D Smith.   

Abstract

Major histocompatibility class II (MHC II) transactivator (CIITA) is critical for interferon-gamma (IFN-gamma)-induced repression of collagen [Xu, Y., Wang, L., Buttice, G., Sengupta, P.K., Smith, B.D., 2004. Major histocompatibility class II transactivator (CIITA) mediates repression of collagen (COL1A2) transcription by interferon gamma (IFN-gamma). J. Biol. Chem. 279, 41319-41332] and activation of MHC II transcription. To better understand the role of CIITA and IFN-gamma induced repression of collagen, mesenchymal cells (lung fibroblasts, adventitial fibroblasts, and smooth muscle cells) were isolated from a CIITA deficient mouse (C2ta(tm1Ccum)). IFN-gamma induced MHC II expression and repressed collagen type I expression in all three cell types isolated from the wild type background. As expected, IFN-gamma treatment of cells isolated from CIITA deficient mice did not induce MHC II production or activate the MHC II promoter. Interestingly, collagen gene expression and promoter activity was similar to that of wild type. Moreover, IFN-gamma induced CIITA mRNA and a truncated form of CIITA protein in all cells isolated from CIITA deficient mice. Most importantly, truncated CIITA occupied the collagen alpha 2(I) gene (col1a2) transcription start site during IFN-gamma treatment, but it did not occupy the MHC II promoter as judged by chromatin immunoprecipitation assays. Exogenous expression of a similar truncated form of CIITA maintained its ability to repress col1a2 transcription, but lost its ability to activate MHC II gene transcription suggesting a role for the CIITA C-terminal domain in activation, but not repression. IFN-gamma induced primarily types I and IV CIITA isoforms in the mouse cells. All three isoforms of CIITA were capable of repressing col1a2 and activating MHC II gene transcription. These data suggest that the previously described CIITA knockout mouse carries a hypomorphic mutation, rather than a null mutation. The removal of the leucine rich region in CIITA blocks activation of MHC II without altering repression of collagen transcription.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982097     DOI: 10.1016/j.molimm.2006.07.294

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

1.  Myocardin-related transcription factor-A complexes activate type I collagen expression in lung fibroblasts.

Authors:  Larry L Luchsinger; Cassandra A Patenaude; Barbara D Smith; Matthew D Layne
Journal:  J Biol Chem       Date:  2011-11-02       Impact factor: 5.157

2.  The effect of class II transactivator mutations on bleomycin-induced lung inflammation and fibrosis.

Authors:  Yong Xu; Larry Luchsinger; Edgar C Lucey; Barbara D Smith
Journal:  Am J Respir Cell Mol Biol       Date:  2010-08-12       Impact factor: 6.914

3.  Major histocompatibility class II transactivator expression in smooth muscle cells from A2b adenosine receptor knock-out mice: cross-talk between the adenosine and interferon-gamma signaling.

Authors:  Yong Xu; Katya Ravid; Barbara D Smith
Journal:  J Biol Chem       Date:  2008-03-21       Impact factor: 5.157

4.  Stable protein, unstable plaque?

Authors:  Nicholas E S Sibinga
Journal:  J Mol Cell Cardiol       Date:  2008-12-03       Impact factor: 5.000

5.  Protein arginine methyltransferase 1 (PRMT1) represses MHC II transcription in macrophages by methylating CIITA.

Authors:  Zhiwen Fan; Jianfei Li; Ping Li; Qing Ye; Huihui Xu; Xiaoyan Wu; Yong Xu
Journal:  Sci Rep       Date:  2017-01-17       Impact factor: 4.379

Review 6.  The MHC Class II Transactivator CIITA: Not (Quite) the Odd-One-Out Anymore among NLR Proteins.

Authors:  Jorge Alfonso León Machado; Viktor Steimle
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.